ATMP trials classification share by disease and development phase globally 2016

This statistic shows the distribution of advanced therapy medicinal product (ATMP) trials worldwide as of 2016, by disease area and phase of development. The share of cancer related ATMP trials in phase I and I/II was 24.2 percent.

Classification of advanced therapy medicinal product (ATMP) trials worldwide as of 2016, by disease area and phase

Phase I and I/IIPhase II II/IIIPhase IIINATotal
------
------
------
------
------
------
------
------
------
------
------
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

April 2016

Region

Worldwide

Survey time period

as of 2016

Supplementary notes

This statistic includes clinical trials from following databases: EudraCT (EU Drug Regulating Authorities Clinical Trials), ClinicalTrials.gov, and ICTRP (International Clinical Trials Registry Platform of the World Health Organization).
The table shows the number of ATMP trials in each disease area: cancer, cardiovascular diseases, immune system/inflammation, musculoskeletal system, neurology, GI diseases and diabetes, ophthalmology, pulmonology, dermatology, haematology, and others. In addition, it shows the percentage of ATMPs targeting every indication by phase of development.
* GI diseases: gastrointestinal diseases.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Cell and gene therapy"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.